MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19 Christine HumJulia LoiselleJohn Paul Pezacki Current Opinion Open access 27 February 2021 Pages: 517 - 531
Pain Management in Chronic Pancreatitis: Summary of Clinical Practice, Current Challenges and Potential Contribution of the M-ANNHEIM Classification Alexander SchneiderMichael Hirth Leading Article 15 February 2021 Pages: 533 - 546
Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer Edward B. GaronPaige Brodrick Leading Article 27 February 2021 Pages: 547 - 554
Post-Dialysis Parenteral Antimicrobial Therapy in Patients Receiving Intermittent High-Flux Hemodialysis Christo CiminoYvonne BurnettAnne H. Norris Review Article 16 February 2021 Pages: 555 - 574
Nintedanib: A Review in Fibrotic Interstitial Lung Diseases Yvette N. Lamb Adis Drug Evaluation Open access 25 March 2021 Pages: 575 - 586
Ravulizumab: A Review in Atypical Haemolytic Uraemic Syndrome Yahiya Y. Syed Adis Drug Evaluation Open access 18 March 2021 Pages: 587 - 594
Comment on “Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update” Udo BonnetHeath McAnallyNorbert Scherbaum Letter to the Editor Open access 18 March 2021 Pages: 611 - 614
Authors’ Reply to Bonnet et al. “Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update” Kirk E. EvoySarvnaz SadrameliAlyssa M. Peckham Letter to the Editor 18 March 2021 Pages: 615 - 617
Correction to: Lonafarnib: First Approval Sohita Dhillon Correction Open access 23 March 2021 Pages: 619 - 619